CD44 and cancer: In addition, we studied CD44 and MSI1, which have been reported to have promoter hypomethylation in triple-negative breast cancers, that is, cancers that lack estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor-2 receptors (HER2) [39].